Add time:07/12/2019         Source:sciencedirect.com

The amino acid-conjugates (1a–k) with eleven amino acids attached to primary amine of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282, 1) were prepared and studied for their prodrug characteristics and anti-cancer activity against SW620 cell line. All the amino acid derivatives showed not only improved water solubility but also displayed potent anti-cancer activity in vitro. Among these amino acid-conjugates the compounds, DW2282-l-Ala (1b), DW2282-l-Phe (1e), DW2282-l-Leu (1g) and DW2282-l-Met (1h) showed good reconversion within 8 h (104.76%, 84.03%, 95.02% and 78.34%, respectively) to the parent drug in human plasma. In addition, the compounds 1e, 1g and 1j also showed good bioavailability profile along with potent in vivo anticancer activity.

We also recommend Trading Suppliers and Manufacturers of N-(4-{[ethyl(phenyl)amino]sulfonyl}phenyl)-2-phenylacetamide (cas 587842-97-5). Pls Click Website Link as below: cas 587842-97-5 suppliers